The impact of cancer waiting times on survival for selected cancers in England,

Similar documents
Variation in optimal pre-diagnostic pathway in lung cancer patients in 2013 & 2014 using cancer registrations and the diagnostic imaging dataset

Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study

Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study

Commentary on NHS Digital. Retrospective Review of Surgery for Urogynaecological Prolapse and Stress Incontinence using Tape or Mesh, April 2018

On-going and planned colorectal cancer clinical outcome analyses

Lung Cancer Diagnostic Pathway Analysis

National Bowel Cancer Audit Supplementary Report 2011

Breast Screening Data Stephen Scott Head of Informatics LCA

Transforming Cancer Services for London

Diagnosing Cancer in Grampian An Academic GP s Perspective

Progress in improving cancer services and outcomes in England. Report. Department of Health, NHS England and Public Health England

National Cancer Registration and Analysis Service Short Report: Chemotherapy, Radiotherapy and Surgical Tumour Resections in England: (V2)

Accelerate, Coordinate, Evaluate (ACE) Programme

NCIN Conference Feedback 2015

National Optimal Lung Cancer Pathways. Dr Sadia Anwar Nottingham University Hospitals NHS Trust Clinical Lead for Lung Cancer

Cancer-specific variation in emergency presentation by sex, age and deprivation across 27 common and rarer cancers

National Bowel Cancer Audit. Detection and management of outliers: Clinical Outcomes Publication

NATIONAL BOWEL CANCER AUDIT The feasibility of reporting Patient Reported Outcome Measures as part of a national colorectal cancer audit

Cost-effective commissioning of colorectal cancer care: An assessment of the cost-effectiveness of improving early diagnosis

Getting it right: Approaches to promoting earlier diagnosis of cancer The national perspective

Accelerate, Coordinate, Evaluate (ACE) Programme

National Cancer Intelligence Network Exploring variations in Routes to Diagnosis for gynaecological cancers, 2006 to 2010

Cancer Outcomes and Services Dataset. What is COSD? Skin Cancers Workshop October 2012

Cancer Alliance Data Pack

Waiting Times for Suspected and Diagnosed Cancer Patients

Chiara Di Girolamo 1,2*, Sarah Walters 1, Sara Benitez Majano 1, Bernard Rachet 1, Michel P. Coleman 1, Edmund Njeru Njagi 1 and Melanie Morris 1

Accelerate, Coordinate, Evaluate (ACE) Programme

Britain against Cancer APPG Cancer Meeting 2009 Research & Technologies Workshop

Informatics in the new NHS : PHE and NCIN 9 months on. Nicky Coombes National Cancer Intelligence Network

National Cancer Intelligence Network short report

Defining, measuring and preventing the diagnosis of cancer as an emergency: a critical review of current evidence

Ambulatory lung biopsy: a new model for the NHS. Dr Sam Hare Barnet Hospital Royal Free London NHS Trust

National Cancer Intelligence Network Routes to Diagnosis:Investigation of melanoma unknowns

WHERE NEXT FOR CANCER SERVICES IN NORTHERN IRELAND? AN EVALUATION OF PRIORITIES TO IMPROVE PATIENT CARE

Investigation of relative survival from colorectal cancer between NHS organisations

National Prostate Cancer Audit. Bill Cross June 2015

Cancer Outcomes and Services Dataset: Implications for clinical teams

Bowel Cancer Quality Improvement Report

Transforming cancer care: the bigger picture and what's next

Impact of cancer symptom awareness campaigns on diagnostic testing and treatment

Bowel Cancer in England and Wales A summary report about the management and outcomes of people with bowel cancer

Re-audit of Radiotherapy Waiting Times 2005

Surveillance of Pancreatic Cancer Patients Following Surgical Resection

INFORMATION TO SUPPORT THE DEVELOPMENT OF THE LINCOLNSHIRE CANCER STRATEGY

Re-audit of Radiotherapy Waiting Times in the United Kingdom, 2007

FIT for symptomatic patients. Facilitator name

Cancer Alliance Data Pack

OFFICIAL. Achieving World-Class Cancer Outcomes: Taking the strategy forward Equality and Health Inequalities Analysis. May

National Diabetes Audit

Routes to diagnosis 2015 update: leukaemia: chronic lymphocytic

UK Bowel Cancer screening Dr Voi Shim Wong BsC MD FRCP. Consultant Gastroenterologist Accredited BCSP colonoscopist Whittington + UCL Hospitals

Routes to diagnosis 2015 update: mesothelioma

Blakely T, Tobias M et al. Tracking disparity: Trends in ethnic and socioeconomic inequalities in mortality, Wellington: Ministry of

Richard Watson, Chief Transformation Officer. Dr P Holloway, GP Clinical Lead for Cancer Lisa Parrish, Senior Transformation Lead

Analysis of One- Year Cancer Survival Rates

UK Complete Cancer Prevalence for 2013 Technical report

to improve the collection and publication of data on chemotherapy activity, outcomes and costs, the chemotherapy dataset will be introduced

Routes to diagnosis 2015 update: multiple myeloma

Wessex Cancer Alliance. Wessex Cancer Strategic Clinical Network

Analysis of One- Year Cancer Survival Rates

Analysis of One- Year Cancer Survival Rates

National Cancer Intelligence Network Short Report

2. CANCER AND CANCER SCREENING

THAMES VALLEY AUDIT OF PATIENTS DIAGNOSED WITH CANCER FOLLOWING AN EMERGENCY PRESENTATION

WHERE NEXT FOR CANCER SERVICES IN WALES? AN EVALUATION OF PRIORITIES TO IMPROVE PATIENT CARE

Lung cancer timed clinical pathways

EARLY DIAGNOSIS: CHALLENGES AND OPPORTUNITIES FOR GPs

West Yorkshire Oral Health Needs Assessment 2015 (Draft)

Raising awareness of cancer symptoms. Amanda Boughey, Cancer Research UK September 2015

Living With and Beyond Cancer where next?

Connecting Cancer Data to Clinical Outcomes Intelligence

Routes to diagnosis 2015 update: liver cancer (excluding intrahepatic bile duct)

DATA quality and KPIs. David Hopkins King s College Hospital London

Analysis of One- Year Cancer Survival Rates

Patient Outcomes in Palliative Care for South Australia

Bladder cancer: National Collaborating Centre for Cancer. diagnosis and management. Clinical Guideline. 28 July 2014.

Using patient data to improve. cancer waiting times. May 2018

Colorectal cancer screening in England

Cancer and Data in the New NHS May Di Riley, Director Clinical Outcomes

Role of evidence from observational studies in the process of health care decision making

Understanding lymphoma: the importance of patient data

Colorectal Pathway Meeting minutes Wednesday 16 th July 2014, 2 pm 4 pm Nightingale Lecture Theatre, UHSM

Revised Standards. S 1a: The service routinely collects data on age, gender and ethnicity for each person referred for psychological therapy.

How a fully integrated Acute Oncology Service can benefit the busy medical unit

Epidemiology, aetiology and the patient pathway in oesophageal and pancreatic cancers

Lewisham Local Authority Cancer JSNA

Survival in Teenagers and Young. Adults with Cancer in the UK

What do we know about GBM Patient pathways in England?

LOOKING BACK FROM THE

Welsh Cancer Intelligence and Surveillance Unit Uned Gwybodaeth a Gwyliadwriaeth Canser Cymru

The primary care perspective Dr Richard Roope

The Manchester Cancer Jaundice Pathway. Derek A. O Reilly Manchester Cancer HPB Pathway Director

National Chronic Kidney Disease Audit

Clinical Decision Support Tool for Cancer (CDS) Project. Evaluation Report to the Department of Health

Using Cancer Registration and MDT Data to Provide Information on Recurrent and Metastatic Breast Cancer

Prevention of Bowel Cancer: which patients do I send for colonoscopy?

Cancer Decision Support Tool (CDS) - FAQ's

Cancer survival in Bhopal, India,

Minimising the consequences of colorectal cancer treatment

Transcription:

The impact of cancer waiting times on survival for selected cancers in England, 2009-2013 Chiara Di Girolamo 1, Carolynn Gildea 2, Melanie Morris 1, Sara Benitez Majano 1, Sarah Walters 1 1 Cancer Policy Programme London School of Hygiene & Tropical Medicine 2 National Cancer Registration and Analysis Service Public Health England Improving health worldwide csg.lshtm.ac.uk @csg_lshtm Background Cancer waiting times are set to determine how long a patient with a suspected cancer should wait to be diagnosed and/or treated. Cancer referral date Date first seen Date of decision to treat Treatment start date Two Week Wait 31-day target (decision to treat to first or subsequent treatment) 62-day target (referral to first treatment) Cancer waiting times pathways and targets (adapted from Cancer Waiting Times: A Guide, version 9.0) In 2003 the National Cancer Waiting Times Monitoring Dataset came into effect to keep track of these targets. 1

Data sources and objectives Cancer Waiting Times Monitoring Dataset Cancer registration data Hospital Episode Statistics Route to diagnosis dataset Audit data (when available) Individual demographic and clinical information on adults aged 15-99 years diagnosed with colorectal, lung or ovarian cancer in England during 2009-2013 Objectives: 1) To describe and compare characteristics of the patients included in the CWT dataset and those not included; 2) Among those with CWT information, to describe and compare characteristics of patients for whom targets were and were not met; 3) To assess the impact of meeting the 31-day wait, the two week wait and the 62-day wait targets on one-year net survival. Results: CWT matching record How many patients did not have a CWT matching record? What were their characteristics? 164,890 colorectal cancer patients 171,208 lung cancer patients 24,545 ovarian cancer patients Who is not in the CWT dataset: 1) Patients who died before treatment could commence 2) Patients who received treatment in private settings 18% 24% 23% - Youngest (<45 yrs) and oldest age groups (>75 yrs) - High (>=5) Charlson comorbidity score - Least deprived (only colorectal and ovarian) - Late or missing stage at diagnosis - Diagnosed through an emergency presentation - Significantly poorer one-year survival Generalisability of findings? Potential for selection bias? 2

Results: two week wait target How many patients were seen within two weeks of GP referral? What are their characteristics? What is the impact on survival of being seen within two weeks of GP referral? Cancer site % target met Colon & rectum 95.1 Lung 97.4 Ovary 97.8 Proportions of patients for whom the target was met were higher among: colorectal cancer patients aged more than 75 years lung and ovarian cancer patients aged less than 45 years Results: 31-day wait target How many patients were treated within 31 days of decision to treat? What are their characteristics? Cancer site % target met Colon & rectum 96.7 Lung 97.7 Ovary 98.3 Around 50% of the patients were treated within 10 days. Quickest in being treated were: late stage patients patients receiving treatments with palliative intent, given active monitoring, or declining the treatment young colorectal cancer patients and old lung cancer patients 3

Results: 31-day wait target What is the impact on survival of receiving the first treatment within 31 days of decision to treat? Waiting time paradox / Sicker quicker effect (Crawford et al, 2002; Forrest et al, 2014) Results: 62-day wait target How many patients were treated within 62 days of GP referral? What are their characteristics? Cancer site % target met Colon & rectum 73.1 Lung 74.8 Ovary 85.5 Quickest in being treated among those coming through the urgent GP referral path: patients receiving treatments with palliative intent, given active monitoring, or declining the treatment patients younger than 75 years 4

Results: 62-day wait target What is the impact on survival of being treated within 62 days of GP referral? Waiting time paradox / Sicker quicker effect (Crawford et al, 2002; Forrest et al, 2014) Discussion and conclusion CWT dataset coverage may limit generalisability of findings and introduce selection bias Time to treatment is impacted by how sick the patient is paradoxical effect of (quick) treatment on survival Treatment with palliative intent is given earlier in time Treatment with potentially curative intent requires more time for additional investigations and planning Beyond survival, benefit to patients of the CWT targets of the actual reduction in time waiting sets cancer apart from other diseases in order for cancer patients to be treated more quickly cuts out very large delays which would impact survival negatively reduces stress/anxiety caused by extended waits 5

Acknowledgements Cancer Policy Programme team: Sara Benitez Majano Chiara Di Girolamo Melanie Morris Patrick Muller Sarah Walters Thanks to: Carolynn Gildea (PHE) Emily Maxwell (CRUK) Nick Ormiston-Smith (CRUK) Thanks to Cancer Research UK: Early Diagnosis Advisory Group Cancer Policy Programme Scientific Advisory Group Improving health worldwide http://csg.lshtm.ac.uk @csg_lshtm 6